Recon: New Zealand signs deal with Pfizer, BioNTech for 1.5M vaccine doses; Mallinckrodt files for bankruptcy

• Pfizer trying to defuse critics amid push for vaccine before Election Day (Politico)
• Trump’s Testimonial Is a Double-Edged Sword for Regeneron (NYTimes)
• Can Trump Really Speed Approval of Covid Treatments? (NYTimes)
• First, a Vaccine Approval. Then ‘Chaos and Confusion.’ (NYTimes)
• Abbott wins US emergency use authorization for new COVID-19 antibody test (Reuters)
• US should not approve vaccine based on UK trials, says Pelosi (FT)
• Alkermes likely headed for approval after adcomm waves through schizophrenia and bipolar program (Endpoints) (Pink Sheet) (BioPharmaDive)
• Mallinckrodt, beset by opioid drug suits, files for bankruptcy (BioPharmaDive)

• WHO says 180-plus countries including China committed to vaccine effort (Reuters)
• New Zealand signs deal with Pfizer, BioNTech for COVID-19 vaccine (Reuters)
• Second human trials of Russian COVID-19 vaccine abroad, in UAE, have launched – Kremlin (Reuters)
• Thailand to make, supply AstraZeneca's COVID-19 vaccine (Reuters)
• South Korea's Celltrion gets approval for Phase 3 trials of COVID-19 antibody drug (Reuters)
• South Korea's Daewoong Pharma gets approval for Phase 1 trials of COVID-19 anti-parasite drug (Reuters)
• Can India, S Africa COVID-19 IPR Waiver Request Gain Traction? (Pink Sheet)

• UK study tests if BCG vaccine protects against COVID (Reuters)
• FDA's Hahn to Topol: Decisions Will Be Made Based on Science Alone (Medscape)
• Covid virus ‘survives for 28 days’ in lab conditions (BBC)
• Trump's Doctor Says There's No 'Actively Replicating Virus' — So Is He COVID-19 free? (NPR)
• White House Blocked C.D.C. From Requiring Masks on Public Transportation (NYTimes)
• A Coronavirus Vaccine Could Kill Half A Million Sharks, Conservationists Warn (NPR)
• Call For Administration's COVID-19 Vaccine Contracts To Be Disclosed (NPR)
• Nevada Revokes Halt on Rapid Antigen Testing in Nursing Homes (NYTimes)
• Regeneron board member and executive sell $1 million in stock after Trump touts treatment (NBC)
• Whistleblower On How Political Pressure Affects Safety Of Coronavirus Vaccines (NPR)
• Two Black university leaders urged their campuses to join a Covid-19 vaccine trial. The backlash was swift (STAT)
• AstraZeneca gets a $500M antibody contract, yet key questions still loom for Trump's new favorite treatment (Endpoints)
• Roche, Abbott, LDTs are most used COVID-19 tests as supply chain constraints force labs to diversify (MedtechDive)

• FDA new drug approvals in Q3 2020 (Nature)
• FDA sends small biotech and its reformulated pain med packing, triggering a collapse in the share price (Endpoints)
• ‘We have to deal with uncertainty’: FDA leaders explain how Covid-19 has upended cancer research and care (STAT)
• Time For Independent FDA? COVID-19 Political Pressure Reignites Debate (Pink Sheet)
• OxyContin Abuse-Deterrent Postmarketing Data Are In. Now What? (Pink Sheet)
• EU Regulatory Network 'Competing With Google' For Tech & AI Experts (Pink Sheet)
• French To Speed Up Early Access Procedure (Pink Sheet)
• UK MHRA Picks Pharmacovigilance For First AI Guideline (Pink Sheet)
• Bob Langer-backed spinout shoots for $75M-plus IPO while biotech SPACs continue to rule on Wall Street (Endpoints)
• News briefing: Gilead reveals more filgotinib data; Seagen and Astellas report new cohort for Padcev (Endpoints)
• Lilly shows more positive Crohn's data for its IL-23 inhibitor as it continues to chase down rivals (Endpoints)
• Novartis vets get $35M to pluck one of the pharma giant’s abandoned drugs off the shelf and put it back into a clinical trial (Endpoints)
• Sami Anwar raked in millions of dollars gathering drug trial data at his sites. But it was all a lie — and now he's been sentenced to 28 years (Endpoints)

• 5 key exec insights from 2020's MedTech Conference (MedtechDive)
• Olympus to roll out colonoscopy AI for spotting lesions, polyps in real time (Fierce)
• HIMSSCast: Is the FDA taking digital health regulation in the right direction? (Mobihealthnews)

• Negotiation Class Wants 6th Circ. Full Review In Opioid MDL (Law360)
• Opioid MDL Bellwether Trial Delayed Amid COVID-19 Fears (Law360)
• J&J Opens Appeal By Assailing 'Radical' $465M Opioid Verdict (Law360)
• Drug Cos. Fight Class Cert. For 'Opioid Babies' In MDL (Law360)
• Prosthetic Maker Reaches Deal Over FTC's Merger Unwinding (Law360)
• Allergan Escapes Ill. Suit Over Defective Breast Implants (Law360)
• Eye Device Maker Gets Rival Product Blocked During IP Fight (Law360)